Document:

Exhibit 10.11

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT
(the “Agreement”) is made as of the date set forth in Schedule A to this Agreement by and between the
individual named in Schedule A (the “Employee”) and TransCode Therapeutics, Inc., a Delaware corporation, with
its principal office at 6 Liberty Square - #2382, Boston, Massachusetts 02109, (the “Company”). The Agreement
becomes effective (the “Effective Date”) upon the earlier to occur of (i) receipt by the Company of at least
$5 million in funding resulting from the issuance of equity, debt having an initial maturity of three years or more, or funds from a strategic
transaction including but not limited to licensing, partnership, development programs, government contracts or awards, sales of rights,
or otherwise, or (ii) execution of an underwriting or other financing agreement involving a transaction for at least $5 million.

 

WHEREAS, the Company
wishes to have the Employee serve in the position set forth in Schedule A and pursuant to this Agreement;

 

WHEREAS, the Company
desires to hire the Employee, and the Employee desires to accept such employment on the terms and conditions set forth in this Employment
Agreement and Schedule A, attached hereto; and

 

WHEREAS, the Employee’s
position requires that he or she continue to be trusted with extensive confidential information and trade secrets of the Company and that
to improve and extend the Company’s business, Employee will need to maintain as thorough and comprehensive knowledge of the Company’s
business as is practical under the terms and conditions set forth herein;

 

NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration of the mutual covenants
herein contained, the parties hereto agree to the terms of Employee’s employment as follows:

 

1.       Position
and Responsibilities. On and after the Effective Date, Employee shall serve in the position and with the title and immediate supervisor
set forth in Schedule A. Employee shall exercise such powers and comply with and perform such directions and duties regarding the business
and affairs of the Company that are customary for Employee’s position and as may be given him or her from time to time by Employee’s
immediate supervisor, the President and Chief Executive Officer (the “CEO”) if different than Employee’s
immediate supervisor, or the Board of Directors of the Company (the “Board”). Employee shall use all diligent
efforts consistent with the terms and conditions set forth herein to improve and extend the business of the Company. Employee agrees to
devote substantially all his or her available business time, attention, and services to the discharge of Employee’s duties for the
best interest of the Company. Any involvement with another for-profit company, such as becoming a member of the board of directors of
such company, shall require the advance written approval of the CEO or the Board, as applicable.

 

2.       Salary,
Equity Participation, and Other Benefits. During the Term of this Agreement (as defined below), Company shall provide Employee
with the compensation and benefits, less all voluntary and legally-required deductions and tax withholdings, as set forth herein and in
Schedule A:

 

		(A)	Base Salary. A salary paid in accordance with the Company’s payroll practices in effect
from time to time which salary annualizes to the amount set forth in Schedule A.

 

		(B)	Bonus. Bonuses are not guaranteed and are granted based on the discretion of the Board and
compensation Committee, taking into account the Company’s financial position and business prospects. Employee shall be eligible
for the target bonus set forth in Schedule A (expressed as a percentage of annualized base salary) based upon targets, goals and objectives
established in good faith by Employee and the Board.

 

    

     

    

 

		(C)	Reimbursement of Expenses; Fringe Benefits. In addition to the arrangements set forth in
Schedule A, Employee will also be entitled to be promptly reimbursed for all business-related travel, lodging, entertainment, supplies
and other reasonable expenses in accordance with the Company’s prevailing policy. Employee will be entitled to participate on the
same basis with all other Company officers and employees in Company’s standard benefits package made generally available to all
other officers and employees, including 401(k), group health, dental, disability and life insurance programs, and other fringe benefits
as may be provided from time to time.

 

		(D)	Time Off. Employees shall be eligible to accrue paid time off (“PTO”) during
each payroll period subject to the Company’s PTO policy as in effect from time to time at the annual rate set forth in Schedule
A. Unused PTO may be carried over into the next following year but any such carried over PTO must be utilized within the first six months
of that following year or be forfeited. Any other treatment of PTO is subject to written arrangements between Employee and Company in
advance or when Company precludes Employee’s use of PTO for business reasons, in which case it must be used within six months of
the dates requested. PTO may be taken at such times as is reasonably prudent and consistent with the proper and diligent performance by
the Employee of his or her duties and responsibilities hereunder, taking into consideration that all Company employees are entitled to
take PTO. In accordance with Massachusetts “Sick Time” law, Employee shall be entitled to five sick days per year in addition
to PTO.

 

Holidays. The Company recognizes
paid holidays as set forth in the Company’s Holiday Schedule available upon request.

 

		(E)	Equity Participation. In addition to any equity related holdings of Employee as of the Effective
Date, Employee shall be entitled to equity incentive awards as defined in Company’s applicable equity incentive plan(s) (each, an
 “Award”) as determined by the Board. If an Award is expressed as a percentage of total common stock, such percentage
shall be calculated on a fully-diluted basis after giving effect to the issuance of all shares of common stock outstanding plus all shares
potentially issuable pursuant to options and other awards under all equity incentive plans of Company in effect at that time of the Award,
warrants to purchase common stock, and instruments convertible into or exchangeable for common stock. Vesting and all other matters related
to the specific terms of the Award shall be set forth in the related Award notice. Unless otherwise provided in writing, vesting of Awards
shall cease as of the Employee’s date of termination, regardless of the reason for such termination.

 

3.       Performance
Review. On not less than an annual basis, the Board and/or Employee’s immediate supervisor shall review Employee’s
performance and the compensation payable to Employee for the prior year and the proposed performance by, and compensation to, Employee
for the then coming year.

 

4.       Term
And Extension. The initial term of this Agreement shall commence on the Effective Date and shall expire on the earlier to
occur of (i) the third anniversary of the Effective Date or (ii) the death or disability of the Employee, (either being the
 “Expiration Date”). Unless notified in writing at least ninety (90) days prior to the Expiration Date, on
each anniversary of this Agreement, this Agreement shall be extended automatically for successive twelve-month periods. The initial
term and any extension of the initial term shall be referred to herein as the “Term” and the Expiration
Date shall be commensurately adjusted. Employee’s employment during the Term is subject to earlier termination as provided
herein. In the event of death or disability, Employee’s estate shall receive payment of all unpaid or accrued salary and the
pro-rata amount (based on the number of days of the applicable fiscal year in which Employee was employed prior to termination) of
the Bonus Target Percentage for such fiscal year applicable to Employee, accrued but unused PTO, and then-vested Awards or other
equity participation then held by Employee (all the foregoing, the “Accrued Obligations”), pro-rated to the Expiration
Date.

 

    2

     

    

 

5.       Early
Termination.  The Term may be terminated prior to the Expiration Date as follows:

 

(A)       At
Company’s Election For Cause. Company may, immediately and unilaterally, terminate Employee’s employment hereunder
for “Cause” at any time during the Term. For purposes of this Agreement, Cause shall mean the occurrence of
one or more of the following events: (i) gross negligence or willful misconduct by the Employee which results, or in the reasonable judgment
of Company may result, in material loss, material damage or material injury (any of the foregoing, “Material Harm”)
to Company; (ii) the commission of an act of embezzlement or fraud; (iii) breach of fiduciary duty which results, or in the reasonable
judgment of Company may result, in Material Harm to Company; (iv) the unauthorized disclosure or misappropriation of any trade secret
or confidential information of Company or any third party to which Company owes a duty of confidentiality; (v) the commission of a wrongful
act which induces any customer or prospective customer, or strategic partner or prospective strategic partner, of Company to breach a
contract with Company or to decline to do business with Company; (vi) the conviction of Employee of a felony or commission of other criminal
act which materially interferes with Employee’s ability to perform his or her services for Company or which results, or in the reasonable
judgment of Company may result, in Material Harm to Company; (vii) the violation or breach (or potential violation or breach) by Employee,
in any material respect, of a non-competition, non-solicitation, non-disclosure, assignment of inventions covenant, or any other agreement,
between Employee and Company; (viii) Employee’s engagement, whether directly or indirectly, during the period of his or her employment
by Company, in a business or other commercial activity which is or may be directly competitive with the business being conducted by Company
at such time; (ix) the solicitation, diversion or taking away by Employee, or the attempted solicitation, diversion or taking away by
Employee, whether directly or indirectly, during the period of his or her employment by Company, of any of the customers, strategic partners,
business or prospective customers of Company then in existence and with whom Employee had contact or about whom Employee gained confidential
information during Employee’s employment, engagement or relationship with Company on behalf of a competitive enterprise (prospective
customer shall mean any person or entity being solicited by Company during the time Employee was employed or engaged by Company); (x)
behavior which materially interferes with Employee’s ability to perform his or her services for Company or which otherwise results,
or in the reasonable judgment of Company may result, in Material Harm to Company; (xi) material failure by Employee to comply with Company’s
written policies or rules after receiving written notification from Company of such failure which notification sets forth in reasonable
detail the basis for such notification and provides a reasonable time and basis for corrective action by Employee; (xii) a continuing
failure by Employee to perform his or her duties or responsibilities in a reasonably acceptable manner after Employee has received written
notification of such failure from Company, so long as Company has provided the resources (human and otherwise) necessary to perform such
duties or responsibilities, has provided reasonably sufficient time for completion of such duties or responsibilities, and such failure
was not a result of others inside or outside the Company failing to perform tasks or activities necessary for Employee to complete his
or her duties or responsibilities; or (xiii) failure of Employee to cooperate in good faith with a governmental or internal investigation
if Company has requested in writing Employee’s cooperation.

 

In the event of any termination
for Cause, Employee shall be entitled to only the Accrued Obligations and no other severance or other compensation or benefits other than
payments or benefits which are required by law to be provided to all terminated employees.

 

(B)       Voluntary
Termination by Employee. The Employee may voluntarily terminate his or her employment at any time during the Term by
providing Company with written notice of termination (such date of voluntary termination the “Voluntary Termination
Date”). In the event of any such voluntary termination by Employee, Employee shall be entitled to the Accrued
Obligations and no other severance, compensation, or benefits other than payments or benefits which are required by law to be
provided to all terminated employees or as may be contractually required by this Agreement or any other written agreement between
Employee and Company or pertaining to Employee.

 

    3

     

    

 

(C)       By
Company for Reasons Other Than Cause. Company may, immediately and unilaterally, terminate Employee’s employment hereunder
at any time during the Term without Cause (the date of such termination, the “Company Election Termination Date”
and, together with the Voluntary Termination Date, each a “Termination Date”).

 

In the event Company exercises
its right to terminate Employee under this Section 5(C) or the Employee resigns for Good Reason (as defined below), in addition to the
Accrued Obligations, Company agrees to pay Employee within ten (10) days a single severance payment equal to (i) Employee’s salary
at the then current rate for that number of months set forth in Schedule A at “Months of Severance” and (ii) an amount equal
to the greater of the incentive compensation paid to the executive in the year prior to the year of termination or that would have been
paid to Employee in or with respect to the year of termination at 100% of the Bonus Target Percentage for the number of months set forth
at “Months of Severance” in Schedule A. Such severance payment shall be subject to withholding of all applicable taxes and
shall be conditioned upon Employee’s execution and non-revocation of a separation agreement substantially in the form attached as
Exhibit A (the “Separation Agreement”) that includes a release of legal claims. In addition to the severance payment, Company
shall pay the premiums for Employee’s health, medical and dental insurances, including those incurred under COBRA, (“Health
Insurances”) for the twelve months following the Termination Date. Notwithstanding the foregoing, if the Employee breaches
any of the provisions contained in Section 6 of this Agreement, all payments of the Severance Amount shall immediately cease.

 

 For purposes of this Agreement, “Good
Reason” shall mean that the Employee has complied with the “Good Reason Process” (hereinafter defined) following
the occurrence of any of the following events: (i) a material diminution in the Employee’s title, responsibilities, authority or
duties; (ii) a diminution in the Employee’s base salary except for across-the-board salary reductions based on the Company’s
financial performance similarly affecting all senior management employees of the Company; (iii) a greater than fifty (50) mile change
in the principal office location at which the Employee provides services to the Company; (iv) the material breach of any provisions of
this Agreement by the Company; or (v) the Company elects not to renew the Term as contemplated in Section 4. “Good Reason Process”
shall mean that (i) the Employee reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the
Employee notifies the Company in writing of the occurrence of the Good Reason condition within 60 days of the Employee obtaining knowledge
of the occurrence of such condition; (iii) the Employee cooperates in good faith with the Company’s efforts, for a reasonable period
not less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such
efforts, the Good Reason condition continues to exist; and (v) the Employee terminates his employment within 60 days after the end of
the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred
in that instance.

 

(D)       Change
in Control Termination Provisions. For purposes of this Agreement, a Change in Control” shall mean (i) any
sale, lease, exclusive license, transfer, distribution or other disposition of all or substantially all of the assets of the Company or
any business unit representing at least fifty percent (50%) of the Company’s activities, (ii) any merger or consolidation of the
Company with or into one or more other entities as a result of which the holders of a majority of the Company’s outstanding voting
stock cease to own a majority of the voting stock of the surviving entity or (iii) any transfer or series of related transfers of a majority
of the outstanding equity securities of the Company designed to be a business combination or acquisition of the Company and not an equity
financing for the purpose of securing working capital.

 

In the event of a termination of
Employee’s employment without Cause or the Employee resigns for Good Reason within eighteen months following, or three (3)
months preceding, any Change in Control (a “Change in Control Termination”), absent Company obtaining an
agreement from any Company successor to assume this Agreement (which assumption shall be subject to Employee’s consent which
consent shall not be unreasonably withheld, delayed or conditioned) and unless otherwise provided herein, Employee shall receive the
following not more than fifteen (15) days after the date (the “Change in Control Termination Date”) of
Employee’s Change in Control Termination:

 

    4

     

    

 

(a) (i) all base salary through the then-current
Expiration Date; (ii) reimbursement for any and all monies advanced by Employee for the time period ending with the Change in Control
Termination Date for all expenses reimbursable by the Company under this Agreement; and (iii) notwithstanding any provision of any
bonus or incentive compensation plan applicable to Employee, a lump sum payment equal to the amount of any bonus or incentive compensation
that has been accrued, allocated, earned by or awarded to Employee for a fiscal year or other measuring period under such plan, or that
would have accrued at the Bonus Target Percentage set forth in Schedule A for that number of months (not to exceed twenty-four) since
Employee’s most recently paid bonus, if any, which period ended on or prior to the Change in Control Termination Date but which
amount has not yet been paid (the foregoing, collectively, “Earned Amounts”); and

 

(b) subject to Employee’s execution of the
Separation Agreement, (i) a lump sum payment in an amount equivalent to (A) the number of months of Employee’s annualized base
salary in effect at the time of termination as set forth at “Months of CIC Severance” in Schedule A and (B) the amount of
bonus for which Employee would have been eligible during the number of months specified in the immediately preceding clause (i)(A) following
the Change in Control Termination Date; (ii) vesting in full of any Awards or other equity interests previously awarded under any
Company equity incentive plan in effect from time to time and outstanding at the Change in Control Termination Date that at such date
remain unvested; (iii) reimbursement by the Company to Employee for any expenses incurred by Employee for payment of premiums for
Health Insurances for the number of months specified in the preceding clause (i)(A) following the Change in Control Termination Date;
and

 

(c) such other benefits, if any, to which Employee
is expressly eligible following a Change in Control Termination as may be provided by then existing plans, programs and/or arrangements
of or with the Company.

 

(E)Section 409A. All forms
of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions
required by law. Employee acknowledges that the Company does not have a duty to design its compensation policies in a manner that minimizes
his or her tax liabilities, and Employee will not make any claim against the Company or the Board related to tax liabilities arising from
Employee’s compensation. Anything in this Agreement to the contrary notwithstanding, if at the time of Employee’s termination
(separation from service within the meaning of Section 409A of the U.S. Internal Revenue Code (the “Code”)),
the Company determines that Employee is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code,
then to the extent any payment or benefit to which Employee becomes entitled under this Agreement on account of Employee’s separation
from service would be considered deferred compensation subject to the 20 percent (20%) additional tax imposed pursuant to Section 409A(a)
of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment will not be payable and such benefit
will not be provided until the date that is the earlier of (A) six (6) months and one day after Employee’s separation from service,
or (B) Employee’s death.

 

If any such delayed cash
payment is otherwise payable on an installment basis, the first payment will include a catch-up payment covering amounts that would
otherwise have been paid during the six-month period but for the application of this provision 5(E), and the balance of the
installments will be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for
reimbursement under this Agreement will be provided by the Company or incurred by Employee during the time periods set forth in this
Agreement. All reimbursements will be paid as soon as administratively practicable, but in no event will any reimbursement be paid
after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits
provided or reimbursable expenses incurred in one taxable year will not affect the in-kind benefits to be provided or the expenses
eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation
or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes
 “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is
payable upon Employee’s termination of employment, then such payments or benefits will be payable only upon Employee’s
 “separation from service.” The determination of whether and when a separation from service has occurred will be made in
accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). Company and Employee intend that this
Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is
ambiguous as to its compliance with Section 409A of the Code, the provision will be read in such a manner that all payments
hereunder comply with Section 409A of the Code. Company makes no representation or warranty and will have no liability to Employee
or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A
of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 

    5

     

    

 

6.       Employee
Confidentiality, Inventions and Noncompetition Agreement. In connection with Employee’s employment
by Company pursuant to the terms of this Agreement, Employee hereby affirms his or her obligations under the Employee Confidentiality,
Inventions and Noncompetition Agreement attached as Exhibit B (the “Noncompetition Agreement”),
the terms and conditions of which are incorporated herein by reference. The Noncompetition Agreement is an essential part of the subject
matter of this Agreement. The parties acknowledge and agree that the Company would not have entered into this Agreement and would not
be offering Employee the consideration set forth herein without also requiring Employee to affirm the Noncompetition Agreement.

 

7.       Governing
Law; Injunctive Relief. This Agreement and the Noncompetition Agreement shall be governed by and construed in accordance with
the internal laws of the Commonwealth of Massachusetts and shall be deemed to be performable in the Commonwealth of Massachusetts. Employee
acknowledges that the breach or threatened breach of any of the provisions of this Agreement or the Noncompetition Agreement may give
rise to irreparable injury to Company which injury may be inadequately compensable in money damages. Accordingly, Company may be entitled
to a restraining order and/or injunction prohibiting the breach or threatened breach of any provision, requirement or covenant of this
Agreement or the Noncompetition Agreement, in addition to and not in limitation of any other legal remedies which may be available. Employee
further acknowledges and agrees that the restrictive covenants set forth in the Noncompetition Agreement are necessary for the protection
of Company’s legitimate goodwill and business interests and are reasonable in scope, duration and content.

 

8.       Severability.
In case any one or more of the provisions contained in this Agreement or the Noncompetition Agreement for any reason shall be held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision
of this Agreement or the Noncompetition Agreement, but this Agreement or the Noncompetition Agreement, as the case may be, shall be construed,
revised, modified and reformed to the maximum extent possible to effect the purposes set forth herein and in the Noncompetition Agreement.

 

9.       Waivers
and Modifications. This Agreement may be modified, and the rights and remedies of any provision hereof may be waived, only
in accordance with this Section 9. No modification or waiver by Company shall be effective without the written consent of Employee,
on the one hand, and the CEO on the other hand. No waiver by either party of any breach by the other party of any provision hereof
shall be deemed to be a waiver of any later or other breach thereof or as a waiver of any other provision of this Agreement. This
Agreement and the Noncompetition Agreement set forth all of the terms of the understandings between the parties with reference to
the subject matter set forth herein and may not be waived, changed, discharged or terminated orally or by any course of dealing
between the parties, but only by an instrument in writing signed by the party against whom any waiver, change, discharge or
termination is sought.

 

    6

     

    

 

10.       Assignment.
Employee acknowledges that the services to be rendered by him or her are unique and personal in nature. Accordingly, Employee may not
assign any of his or her rights, or delegate any of his or her duties or obligations, under this Agreement. The rights and obligations
of Company under this Agreement shall inure to the benefit of, and shall be binding upon, the successors and assigns of Company, including
any successor to Company’s capital stock or assets by reason of a Change in Control, acquisition, merger, sale of capital stock
or assets or other business combination. If a Change in Control occurs and Employee reasonably believes that the financial condition of
Company’s successor is not at least as strong as that of Company, Employee may elect to consider such assignment a constructive
termination as set forth in Section 5C hereof.

 

11.       Acknowledgments.
Employee hereby acknowledges and recognizes that the enforcement of any of the provisions of the Noncompetition Agreement may interfere
with Employee’s ability to pursue certain positions with certain companies in the life sciences industry. Notwithstanding the foregoing,
Employee represents that he or she is knowledgeable about the business of Company and further represents that he or she is capable of
pursuing, and willing to pursue, other positions to earn a proper livelihood.

 

12.       Arbitration.
Any controversy, dispute, claim or breach arising out of or relating to this Agreement shall be submitted for settlement to one arbitrator
agreed upon by the parties. The decision of such arbitrator shall be final and binding on the parties. If the parties cannot agree upon
an arbitrator within 10 days of written notice of a dispute by either party, the controversy, claim or breach shall be referred to the
American Arbitration Association (the “Association”) with a request that the Association appoint an arbitrator.
Such arbitration shall be held in Boston, Massachusetts, in accordance with the rules and practices of the Association pertaining to single-party
employment arbitrations then in effect, and judgment upon the award rendered shall be entered by consent in any court having jurisdiction.
The arbitration hearing shall take place within sixty (60) days of the appointment of the arbitrator, the hearing shall last no longer
than 10 hours on one business day and the arbitrator shall render his or her decision within five (5) business days of the hearing and
shall provide the parties in writing his or her reasoned decision with appropriate explanation. The prevailing party shall be entitled
to recover all or any costs and expenses associated with any arbitration (including attorneys’ fees) at the discretion of the arbitrator;
otherwise, each party shall be responsible for its own expenses.

 

13.       Indemnification.
The Company and the Employee hereby acknowledge their execution as of even date herewith the Company’s standard indemnification
agreement for senior executives attached hereto as Exhibit C.

 

The remainder of this page intentionally left
blank.

 

    7

     

    

 

       IN
WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date set forth in Schedule A hereto. 

 

	TRANSCODE
    THERAPEUTICS, INC.	 
	 	 
	 	By:	/s/
    Robert Michael Dudley	 
	 	Name:	Robert
    Michael Dudley	 
	 	Title:
    CEO	 

  

	EMPLOYEE	 
	 	 
	 	By:	/s/ Thomas A. Fitzgerald	 
	 	Name:	Thomas A. Fitzgerald	 
	 	Title:
    Vice President and Chief Financial Officer	 

 

    8

     

    

 

 

 

Schedule A

 

Employment Agreement between TransCode Therapeutics,
Inc.

 

and

 

Thomas A. Fitzgerald (“Employee”)

 

 

	Agreement
    Date:	March
    24, 2021
	 	 
	Position
    / Title:	Vice
    President of Administration and Chief Financial Officer
	 	 
	Immediate
    Supervisor:	President
    and Chief Executive Officer
	 	 
	Salary:	$360,000
    (annualized as set forth in Section 2A)
	 	 
	Bonus
    Target Percentage:	35%
    of Annualized Base Salary (not guaranteed except as may be set forth in the Employment Agreement)
	 	 
	Intended
    Payroll Schedule:	Twice
    per month
	 	 
	Equity
    Plan Participation:	Percentage
    of Company’s fully diluted shares outstanding on the date of grant: 4.93%
	 	 
	Paid
    Time Off (“PTO”)	20
    days per year accrued per payroll period
	 	 
	Months
    of Severance:	18
    (except in the case of “Change in Control” or “CIC”)
	 	 
	Months
    of CIC Severance:	24
    (only in the case of a “Change in Control Termination”)
	 	 
	Health
    Insurance and/or COBRA:	12
    months of premium will be paid by Company
	 	 

EMPLOYEE:

 

	Thomas
    A. Fitzgerald	 	/s/
    Thomas A. Fitzgerald	 	March
    24, 2021
	Print
    Name	 	Signature	 	Date
	 	 	 	 	 
	COMPANY:	 	 	 	 
	 	 	 	 	 
	Robert
    Michael Dudley	 	/s/
    Robert Michael Dudley	 	3/24/2021
	[President’s
    Name Here]	 	Signature	 	Date

 

    9

     

    

 

Exhibit A

 

Separation Agreement

 

 (Attached)

 

 

Exhibit
B

 

Employee Confidentiality,
Inventions and Noncompetition Agreement

 

(Attached)

 

 

Exhibit
C 

 

Executive
Officer Indemnification Agreement

 

(Attached)

 

    10Exhibit 10.12

 

 

 

March 24, 2021

 

Thomas A. Fitzgerald

39 Nehoiden Road

Waban, MA 02468

 

Dear Tom,

 

On the date of this letter agreement, you and TransCode Therapeutics,
Inc. (the “Company”) entered into an Employment Agreement. This letter is to confirm our mutual understanding that these agreements
become effective upon the Company’s receipt of gross proceeds of $5 million or more from issuances of equity or convertible debt
or from partnering arrangements.

 

Please sign in the space provided below signifying your understanding
of and accord with the effectiveness of the Employment Agreement as set forth in the prior paragraph, then return one signed original
of this letter agreement to the Company. You should retain a copy of this letter agreement as executed with your copy of your Employment
Agreement.

 

Should you have any questions, please contact me.

 

Sincerely,

 

	/s/ R. Michael Dudley	 

R. Michael Dudley

CEO

 

	Read and accepted:	/s/ Thomas A. Fitzgerald	   Date: 	March 24 ,2021
	 	  Thomas A. Fitzgerald	 	 

 

 

TRANSCODE THERAPEUT I C S , I N C . •
6 L I B E R T Y S Q U A R E # 2 3 8 2 • B O S T O N , MA 02109

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]